Our ’Metabolic Acidosis-Market Insights, Epidemiology and Market Forecast_2030’ report delivers an in-depth understanding of metabolic acidosis, historical and forecasted epidemiology as well as the metabolic acidosis market trends in 7 major markets (7MM) in the United States, Germany, France, Italy, Spain, and the United Kingdom, Japan and 3 emerging markets (3EM) Brazil, China, and Mexico.
The metabolic acidosis market report provides current treatment practices, emerging drugs, metabolic acidosis market share of the individual therapies, current and forecasted metabolic acidosis market size from 2017 to 2030 segmented by 7MM+3EM. The report also covers market drivers, market barriers and unmet medical needs to curate the best of the opportunities and evaluates the underlying potential of the market.
Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • Brazil
  • China
  • Mexico



Study Period: 2017–2030
Metabolic Acidosis Disease Understanding and Treatment Algorithm
Metabolic Acidosis Overview
Metabolic acidosis is defined by an increase in the hydrogen-ion concentration in the systemic circulation, which results in a serum bicarbonate (HCO3) <24 mEq/L. It is not a benign condition and shows an underlying disorder that needs to be corrected to minimize morbidity and mortality. The many etiologies of metabolic acidosis are classified mainly into four mechanisms: acid ingestion, increased production of acid, decreased excretion of acid, and renal or gastrointestinal (GI) bicarbonate losses. Metabolic acidosis has been identified as a key risk factor in the progression of chronic kidney disease (CKD)
Metabolic acidosis can be acute or chronic. Acute metabolic acidosis is comparatively more common among severely ill patients than chronic metabolic acidosis. The frequency of chronic metabolic acidosis might increase with the expected rise in CKD in the geriatric population.
Metabolic Acidosis Diagnosis
Metabolic acidosis is generally diagnosed in patients that are affected by CKD and also when the serum tCO2 concentration, which is a substitute for the bicarbonate concentration, is steadily <22 mEq/L. However, low serum tCO2 concentration is also a feature of respiratory alkalosis, and distinguishing this acid–base disorder from metabolic acidosis involves measuring systemic pH and Pco2, preferably from an arterial sample. Blood gases are rarely performed in patients with CKD with low tCO2 concentrations, are not freely available in the outpatient setting, and are needless in most of the cases. But by giving the significance of nonvolatile acid excretion in the kidney, a reasonable diagnosis of metabolic acidosis can be made without a blood gas in a patient with CKD and low tCO2 concentration.

Metabolic Acidosis Treatment
It covers the details of conventional and current medical therapies available in the market for the treatment of metabolic acidosis. It also provides the country-wise treatment guidelines and algorithms across the 7 major markets and 3 emerging markets.
The DelveInsight Metabolic Acidosis market report gives a thorough understanding of metabolic acidosis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
Metabolic Acidosis Epidemiology
Metabolic acidosis epidemiology segment provides insights about historical and current metabolic acidosis patient pool and forecasted trends for 7 major and 3 emerging countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
The prevalence and severity of metabolic acidosis increases from CKD Stage 3 to Stage 5; up to 30% in CKD stage 4 to 5. Overall prevalence of metabolic acidosis in CKD population is ~15%
The total prevalent cases of metabolic acidosis patients were found to be more in males than in females in 7MM+3EM during the study period 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Metabolic Acidosis epidemiology segmented as Total Prevalence of CKD patients, Total Prevalence of Metabolic Acidosis in CKD patients, Total Prevalence of dRTA, Total Diagnosed Population of Metabolic Acidosis, Total Diagnosed Population of dRTA, Gender-Specific diagnosed cases of Metabolic Acidosis, Total Treated Population of Metabolic Acidosis and Total Treated Population of dRTA in 7MM+3EM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, Brazil, China, and Mexico from 2017 to 2030.
Country Wise Metabolic Acidosis Epidemiology
The epidemiology section also provides the metabolic acidosis epidemiology data and key findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, Brazil, China, and Mexico.

  • As per the DelveInsight estimates, the total prevalent cases of metabolic acidosis in 7MM+3EM were 19,982,276 in 2017, which are expected to reach a significantly high number by 2030.
  • As per the DelveInsight analysis, the total prevalent cases of metabolic acidosis in China was found to be 10,125,248 in 2017, which are expected to reach a significantly high number by 2030.
  • As per the DelveInsight analysis, the total diagnosed cases of dRTA in Germany were 1,548 cases in 2017, which are expected to reach a significantly high number by 2030.



Metabolic Acidosis Drug Chapters
This segment of the metabolic acidosis report encloses the detailed analysis of current drug therapies and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the metabolic acidosis clinical trial details, expressive pharmacological actions, agreements and collaborations, approval and awards, advantages and disadvantages of each included drug, and the latest news and press releases.
There are no FDA-approved therapies for long-term treatment of metabolic acidosis in CKD patients; however oral alkali therapies such as sodium bicarbonate, sodium citrate, and potassium citrate/citric acid are currently prescribed by the nephrologists for treatment of metabolic acidosis.
Metabolic Acidosis Emerging Drugs
Veverimer (TRC101): Tricida
Veverimer, which is also known as TRC101, is a novel, nonabsorbed polymer that is designed for the treatment of metabolic acidosis by binding hydrochloric acid in the gastrointestinal tract and removing it from the body through excretion in the feces. It also helps in decreasing the total amount of acid in the body and increasing blood bicarbonate. Veverimer is administered orally as a suspension in water, and it is currently under assessment by the US Food and Drug Administration (FDA) for New Drug Application (NDA) assessment.
ADV7103: Advicenne Pharma
ADV7103 is a pioneering product with a prolonged-release formulation designed to maintain a sustained release over 12 h. The product was developed as a multi particulate formulation in 2mm granules that contains two active pharmaceutical ingredients. This drug molecule is tasteless and easy to administer orally in patients of all ages. It is an investigational drug designed to treat distal renal tubular acidosis (dRTA) in patients of all ages. In December 2019, Advicenne signed a supply agreement with the pharmaceutical contract development and manufacturing organization (CDMO) Elaiapharm Lundbeck for the manufacturing of its lead product ADV7103 with a view to its worldwide commercialization as a treatment for distal Renal Tubular Acidosis (dRTA).
Products detail in the report?
Metabolic Acidosis Market Outlook
The metabolic acidosis market outlook helps to cultivate a detailed comprehension of the historical, current and forecasted market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for the better technology.
This segment gives a thorough detail of metabolic acidosis market trend of each late-stage pipeline therapy by evaluating their impact based on annual cost of treatment, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear picture of the market at first sight.
According to DelveInsight, the therapeutic market of Metabolic Acidosis in 7MM+3EM generated USD 26.89 million in 2017 and is expected to change in the forecast period 2017–2030.

Key Findings

  • Among the EU-5 countries, Germany had the highest market size, with USD 2.29 Million in 2017, while Italy had the lowest market size with USD 0.86 Million in 2017.
  • The market size of metabolic acidosis by therapies in Japan was observed as USD 2.70 Million for oral alkali therapy in 2017.
  • The total market size of metabolic acidosis in Brazil was observed as USD 1.14 Million in 2017.


The United States Market Outlook
This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in the United States.
EU-5 Countries: Market Outlook
This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in Germany, France, Italy, Spain, and the United Kingdom.
Japan Market Outlook
This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in Japan.
Brazil Market Outlook
This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in Brazil.
China Market Outlook
This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in China.
Mexico Market Outlook
This section provides market insights related to the total metabolic acidosis market size and the market size of metabolic acidosis by therapies in Mexico.
Reimbursement Scenario in Metabolic Acidosis
Proactively approaching reimbursement can have a positive impact, not only during the late stages of product development but well after product launch as well. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in and for metabolic acidosis domain through primary research to fill the data gaps, and validate our secondary research. Their opinion helps us to understand and verify current and emerging therapies treatment patterns or current market trends. It will also support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Metabolic Acidosis market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the availability of the data.
Scope of the Report

  • The report covers the descriptive overview of Metabolic Acidosis, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Metabolic Acidosis epidemiology and treatment in the 7MM+3EM.
  • Additionally, an all-inclusive account of both the current therapeutic strategies and emerging therapies for Metabolic Acidosis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Metabolic Acidosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM+3EM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the Global Metabolic Acidosis market



Report Highlights

  • In the coming years, metabolic acidosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the market size to enable the drug manufacturers to penetrate more into the market.
  • The companies and researchers are working to overcome the challenges and seek opportunities that could help them to develop specific therapies for the treatment of metabolic acidosis. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Launch of emerging therapies will significantly impact the metabolic acidosis market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Metabolic Acidosis.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


Metabolic Acidosis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Metabolic Acidosis Pipeline Analysis
  • Metabolic Acidosis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Metabolic Acidosis Report Key Strengths

  • 11-Year Forecast
  • 7MM+3EM Coverage
  • Metabolic Acidosis Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake


Metabolic Acidosis Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • Conjoint Analysis


Key Questions
Market Insights:

  • What was the Metabolic Acidosis Market share (%) distribution in 2017, and how would it look like in 2030?
  • What would be the Metabolic Acidosis total market size as well as market size by therapies across the 7MM+3EM during the study period (2017_2030)?
  • What are the key findings pertaining to the market across 7MM+3EM and which country will have the largest Metabolic Acidosis market size during the study period (2017–2030)?
  • At what CAGR, the Metabolic Acidosis market is expected to grow in 7MM+3EM during the study period (2017–2030)?
  • What would be the Metabolic Acidosis market outlook across the 7MM+3EM during the study period (2017–2030)?
  • What would be the Metabolic Acidosis market growth till 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
  • How does the market size look like for the market size by therapies for each 7MM+3EM? And what are the treatment options for metabolic acidosis and revenue these treatment options expected to garner?
  • Which patient segment or type of therapy is more lucrative in Metabolic Acidosis? And where the emerging therapies are focusing more?


Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of the Metabolic Acidosis?
  • What is the historical Metabolic Acidosis patient pool in 7MM+3EM covering the United States, EU5 (Germany, Spain, France, Italy, the United Kingdom), Japan, China, Brazil, and Mexico?
  • What is the historical dRTA patient pool in 7MM+3EM covering the United States, EU5 (Germany, Spain, France, Italy, the United Kingdom), Japan, China, Brazil, and Mexico?
  • What would be the forecasted patient pool of Metabolic Acidosis in 7MM+3EM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, Brazil, and Mexico?
  • What would be the forecasted patient pool of dRTA in 7MM+3EM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, Brazil, and Mexico?
  • What will be the growth opportunities in the 7MM+3EM for the patient population pertaining to Metabolic Acidosis?
  • What will be the growth opportunities in the 7MM+3EM for the patient population pertaining to dRTA?
  • Out of all 7MM+3EM countries, which country would have the highest prevalent population of metabolic Acidosis during the study period (2017–2030)?
  • Out of all 7MM+3EM countries, which country would have the highest prevalent population of dRTA during the study period (2017–2030)?
  • At what CAGR the population is expected to grow in 7MM+3EM during the study period (2017–2030)?
  • What are the currently available treatments of limited and extensive Metabolic Acidosis? And how the prescription patterns look like across the therapies and how does it differ across the 7MM+3EM?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Metabolic Acidosis along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Metabolic Acidosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, Brazil, and Mexico?
  • What are the Metabolic Acidosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Metabolic Acidosis?
  • How many therapies are developed by each company for the treatment of a Metabolic Acidosis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metabolic Acidosis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Metabolic Acidosis and their status?
  • What are the key designations that have been granted for the emerging therapies for Metabolic Acidosis?
  • What are the global historical and forecasted market of Metabolic Acidosis?



Reasons To Buy
_ The report will help in developing business strategies by understanding trends shaping and driving the Metabolic Acidosis market.
_ To understand the future market competition in the Metabolic Acidosis market and Insightful review of the key market drivers and barriers.
_ Organize sales and marketing efforts by identifying the best opportunities for Metabolic Acidosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, China, Brazil, and Mexico.
_ Identification of strong upcoming players in the market will help in planning strategies that will help in getting ahead of competitors.
_ Organize sales and marketing efforts by identifying the best opportunities for Metabolic Acidosis market.
_ To understand the future market competition in the Metabolic Acidosis market.